Catalog No.: PC-20193Not For Human Use, Lab Use Only.
LY2090314 is a potent and selective ATP-competitive inhibitor of Glycogen synthase kinase-3 (GSK-3) with IC50 of 1.5/0.9 nM for GSK3α/GSK3β, respectively.
LY2090314 is a potent and selective ATP-competitive inhibitor of Glycogen synthase kinase-3 (GSK-3) with IC50 of 1.5/0.9 nM for GSK3α/GSK3β, respectively.
LY2090314 stimulated TCF/LEF TOPFlash reporter activity, stabilized β-catenin and elevated the expression of Axin2 in a panel of melanoma cell lines at nM potency.
LY2090314 exhibited cytotoxicity against melanoma cell lines in vitro with IC50 of 10 nM, but not other solid tumor cell lines (IC50 >10 uM).
LY2090314 elevates Axin2 gene expression after a single dose and produces tumor growth delay in A375 melanoma xenografts with repeat dosing.
